162 related articles for article (PubMed ID: 28247605)
1. [Efficacy of adjuvant endocrine therapy in breast cancer patients with a positive-to-negative switch of hormone receptor status after neoadjuvant chemotherapy].
Xia G; Zhu J; Yuan J; Cao B; Tang J; Chen Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(6):614-619. PubMed ID: 28247605
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
3. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
Jin X; Jiang YZ; Chen S; Yu KD; Shao ZM; Di GH
Oncotarget; 2015 Apr; 6(11):9600-11. PubMed ID: 25826079
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
7. Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.
Bedognetti D; Sertoli MR; Pronzato P; Del Mastro L; Venturini M; Taveggia P; Zanardi E; Siffredi G; Pastorino S; Queirolo P; Gardin G; Wang E; Monzeglio C; Boccardo F; Bruzzi P
J Natl Cancer Inst; 2011 Oct; 103(20):1529-39. PubMed ID: 21921285
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases.
van Nijnatten TJ; Simons JM; Moossdorff M; de Munck L; Lobbes MB; van der Pol CC; Koppert LB; Luiten EJ; Smidt ML
Breast Cancer Res Treat; 2017 May; 163(1):159-166. PubMed ID: 28213782
[TBL] [Abstract][Full Text] [Related]
9. Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology).
Inal A; Akman T; Yaman S; Demir Ozturk S; Geredeli C; Bilici M; Inanc M; Harputoglu H; Demirci U; Balakan O; Yesil Cinkir H; Alici S; Uysal Sonmez O; Goksel G; Gokoz Dogu G; Umit Unal O; Tamozlu T; Buyukberber S; Melih Boruban C; Isikdogan A
J BUON; 2013; 18(1):64-9. PubMed ID: 23613390
[TBL] [Abstract][Full Text] [Related]
10. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
Resende U; Cabello C; Ramalho SOB; Zeferino LC
BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.
Koca E; Kuzan TY; Dizdar O; Babacan T; Sahin I; Ararat E; Altundag K
Med Oncol; 2013; 30(3):615. PubMed ID: 23729267
[TBL] [Abstract][Full Text] [Related]
12. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of adjuvant endocrine therapy and hormone receptor status change following neoadjuvant chemotherapy in breast cancer patients.
Wu JY; Chen WG; Chen XS; Huang O; He JR; Zhu L; Li Y; Shen KW; Chow LW; Loo WT; Chow CY; Tsang W
Int J Biol Markers; 2014 Dec; 29(4):e380-6. PubMed ID: 25385240
[TBL] [Abstract][Full Text] [Related]
14. Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer.
Adachi Y; Oze I; Sawaki M; Hattori M; Yoshimura A; Kotani H; Kataoka A; Sugino K; Horisawa N; Ozaki Y; Endo Y; Nozawa K; Takatsuka D; Iwata H
Breast Cancer; 2021 Sep; 28(5):1087-1095. PubMed ID: 33886077
[TBL] [Abstract][Full Text] [Related]
15. [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy].
Rong QL; Wang SL; Tang Y; Jin J; Song YW; Wang WH; Liu YP; Fang H; Ren H; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):445-452. PubMed ID: 28635235
[No Abstract] [Full Text] [Related]
16. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.
Daly B; Olopade OI; Hou N; Yao K; Winchester DJ; Huo D
JAMA Oncol; 2017 Jul; 3(7):928-935. PubMed ID: 28152150
[TBL] [Abstract][Full Text] [Related]
18. Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab.
Wang X; Cai L; Ye F; Li M; Ma L; Geng C; Song Z; Liu Y
Medicine (Baltimore); 2019 Sep; 98(36):e16937. PubMed ID: 31490377
[TBL] [Abstract][Full Text] [Related]
19. Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
Tsai J; Bertoni D; Hernandez-Boussard T; Telli ML; Wapnir IL
Ann Surg Oncol; 2016 Oct; 23(10):3310-6. PubMed ID: 27401442
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
